Abstract: The invention pertains in a first aspect to a multilayer film that includes a frangible holographic image layer and an adhesive layer adjacent to a side of the holographic image layer; and, an additional temporary support layer that is adjacent a side of the holographic image layer that is opposite the adhesive layer, and provides integrity to the multilayer film. The additional temporary support layer can be a polyester film that is removable from the multilayer film at ?10 gram per inch peel strength; or, can be a heat-shrinkable film that is removable from the multilayer film with the application of heat. After application of the multilayer film to a substrate, the holographic image layer forms an exterior surface of the multilayer film.

Abstract: In a first aspect, a multilayer film includes a holographic image layer, a first heat-shrinkable layer and a first adhesive layer between the holographic image layer and the first heat-shrinkable layer. In a second aspect, an authentication label includes a holographic image layer, a first heat-shrinkable layer, a first adhesive layer between the holographic image layer and the first heat-shrinkable layer, and a back adhesive layer.

Abstract: The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in one of FIGS. 1-10.

Abstract: A process for making (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile and salts thereof, and intermediates used in the process are disclosed.

Abstract: Disclosed are crystalline forms of a compound of formula (I), methods of their preparation, and related pharmaceutical preparations thereof.

Abstract: A process for making (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile and salts thereof, and intermediates used in the process are disclosed.

Abstract: The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in one of FIGS. 1-10.

Abstract: An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract: Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.

Abstract: A method and element for both authenticating and labeling a product or packaging for a product utilizes a hologram label that is applied over a barcode, such that the barcode and label can be located in the same space on the product or packaging to minimize space requirements. The underlying barcode can still be read using conventional barcode readers, such as laser scanners and image scanners. The barcode can be of various types including both linear barcode and two-dimensional barcode. The barcode is advantageously read with a barcode reader which is positioned at an acute angle with respect to a normal line to a surface bearing the barcode.

Abstract: A multicolor hologram (e.g., a two-color hologram) is replicated (copied) into a photosensitive layer by masking to produce a copy (replicate) of the hologram in a manner such that the copy is an accurate and true replication of the hologram (e.g., master hologram) and the copy is characterized to possess a high brightness level and color fidelity comparable to that of the multicolor hologram that was replicated. Both flood and scan modes can be employed in the replication.

Abstract: A hologram (and related hologram element) contains and exhibits a holographic image when illuminated and viewed on angle and with the holographic image gradually fading when viewed increasingly off angle in 1st-3rd directions. This hologram also contains and exhibits a monochrome wash surface that obscures (partially or totally) the holographic image when viewed in a 4th direction as the hologram is increasingly rotated off angle in a 4th direction through a range of angles. The hologram can be fabricated with a variety of color choices for the monochrome wash surface. The hologram is useful in security and authentication applications and is used in a method provided herein for authentication of an article.

Abstract: A multicolor hologram (e.g., a two-color hologram) is replicated (copied) into a photosensitive layer by masking to produce a copy (replicate) of the hologram in a manner such that the copy is an accurate and true replication of the hologram (e.g., master hologram), and the copy is characterized to possess a high brightness level and color fidelity comparable to that of the multicolor hologram that was replicated. Both flood and scan modes can be employed in the replication.

Abstract: An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis-HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of the composition, in a pharmaceutically acceptable carrier; wherein said active ingredient is in solid-state form and/or the composition further comprises, dispersed in the carrier, a pharmaceutically acceptable heavier-chalcogen antioxidant in an amount effective to inhibit oxidation of the active ingredient at a thioether linkage thereof. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract: An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract: An orally deliverable pharmaceutical composition comprises a drug-carrier system having a Bcl-2 family protein inhibitory compound, e.g., ABT-263, in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract: Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.

Abstract: A method is provided for replicating (copying) a multicolor hologram (e.g., a two-color hologram) into a photosensitive layer by masking to produce a copy (replicate) of the hologram in a manner such that the copy is an accurate and true replication of the hologram (e.g., master hologram) and the copy is characterized to possess a high brightness level and color fidelity comparable to that of the multicolor hologram that was replicated.

Abstract: A holographic optical element (HOE) that includes a deep image hologram and a method for using this HOE as a security device are described. The deep image hologram is viewable with a collimated or at least partially collimated light source having a center wavelength in the visible region of the electromagnetic spectrum and a spectral bandwidth, wherein the spectral bandwidth of the collimated or at least partially collimated light source at least partially overlaps the spectral bandwidth of the deep image hologram. The deep image hologram is not viewable (i.e., appears essentially unrecognizable to the human eye) with a diffuse lighting source, such as ordinary room lighting.

Abstract: The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in one of FIGS. 1-10.